Ruban Mangadu

917 total citations
15 papers, 579 citations indexed

About

Ruban Mangadu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Ruban Mangadu has authored 15 papers receiving a total of 579 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 3 papers in Immunology. Recurrent topics in Ruban Mangadu's work include Cancer Immunotherapy and Biomarkers (5 papers), CAR-T cell therapy research (2 papers) and TGF-β signaling in diseases (2 papers). Ruban Mangadu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), CAR-T cell therapy research (2 papers) and TGF-β signaling in diseases (2 papers). Ruban Mangadu collaborates with scholars based in United States and Germany. Ruban Mangadu's co-authors include Ying Jing, Linda S. Higgins, Darren H. Wong, Ramona G. Almirez, Jörg Wischhusen, Steffen Aulwurm, Michael Weller, Wolfgang Wick, Michael Platten and Markus Weiler and has published in prestigious journals such as Cancer Research, Scientific Reports and Pain.

In The Last Decade

Ruban Mangadu

13 papers receiving 562 citations

Peers

Countries citing papers authored by Ruban Mangadu

Since Specialization

Citations

This map shows the geographic impact of Ruban Mangadu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruban Mangadu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruban Mangadu more than expected).

Fields of papers citing papers by Ruban Mangadu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruban Mangadu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruban Mangadu. The network helps show where Ruban Mangadu may publish in the future.

Co-authorship network of co-authors of Ruban Mangadu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruban Mangadu. A scholar is included among the top collaborators of Ruban Mangadu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruban Mangadu. Ruban Mangadu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract 4364: Preclinical pharmacokinetics and pharmacodynamics of MK-4464, a novel NK cell engager targeting CEACAM5 2025 ·Cancer Research ·Tapan K. Nayak, (unknown), Li Li, Sophie H. Li, Smita Mauze, Mingmei Cai, Ruban Mangadu, Kerry Riffel, Xiangjun Meng, (unknown), Konstantin Dobrenkov, Amy M. Beebe	0
2	STUB1 is an intracellular checkpoint for interferon gamma sensing 2022 ·Scientific Reports ·Simon Ng, Shuhui Lim, (unknown), Ruban Mangadu, Ally Lau, Chunsheng Zhang, (unknown), Arun Chandramohan, (unknown), (unknown), Shih Chieh Chang, Pooja Gopal, Lewis Z. Hong, Adam G. Schwaid, Aaron Z. Fernandis, Andrey Loboda, Cai Li, Uyen Phan, Brian Henry, Anthony W. Partridge	4
3	Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programed cell death 2022 ·Cell chemical biology ·Shih Chieh Chang, Pooja Gopal, Shuhui Lim, (unknown), (unknown), Ruban Mangadu, Jeffrey S. Smith, Simon Ng, Marian E. Gindy, Uyen Phan, Brian Henry, Anthony W. Partridge	19
4	High-Resolution Ex Vivo Tissue Clearing, Lightsheet Imaging, and Data Analysis to Support Macromolecular Drug and Biomarker Distribution in Whole Organs and Tumors 2022 ·Microscopy and Microanalysis ·Niyanta Kumar, (unknown), (unknown), Jindřich Soukup, (unknown), Tomoko Freshwater, Sophia Bardehle, (unknown), (unknown), Ruban Mangadu, Cinthia V. Pastuskovas, Mark T. Cancilla	1
5	A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model 2020 ·Journal of Immunotoxicology ·(unknown), Beth Hutchins, Sheri Dubey, Nianyu Li, Rupesh P. Amin, Stephanie Born, Ruban Mangadu, Joseph H. Phillips, Venkataraman Sriram, Danuta J. Herzyk	2
6	Abstract 543: Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab 2016 ·Cancer Research ·Elaine M. Pinheiro, (unknown), Ruban Mangadu, Mingmei Cai, Uyen Phan, Michael Nebozhyn, Heather A. Hirsch, Andrey Loboda, Sarah Javaid, Yaolin Wang, Venkataraman Sriram, Joseph H. Phillips, Terri McClanahan, Brian J. Long	0
7	Development of the anti-IL-10 mAb MK-1966 in combination with in situ vaccination of a TLR9 agonist SD-101 for cancer immunotherapy 2016 ·European Journal of Cancer ·Uyen Phan, Ryo Ueda, Ruban Mangadu, Manjiri Sathe, (unknown), (unknown), Gulesi Ayanoglu, Yingzhe Yu, Jerelyn Wong, Svetlana Sadekova, Terri McClanahan, (unknown), Aarron Willingham, Richard F. Raubertas, Rob Kastelein	1
8	In vivo anti-tumor efficacy of afucosylated anti-CS1 monoclonal antibody produced in glycoengineered Pichia pastoris 2015 ·Journal of Biotechnology ·(unknown), Drake LaFace, Nga Rewa Houston-Cummings, Ruban Mangadu, Renée Moore, (unknown), (unknown), Huijuan Li, Terrance A. Stadheim, Dongxing Zha	5
9	Abstract 269: Evaluation of the antitumor activity of anti-PD-1 immunotherapy as a single agent and in combination with approved agents in preclinical tumor models 2015 ·Cancer Research ·Elaine M. Pinheiro, Ruban Mangadu, Uyen Phan, Mingmei Cai, Yanhong Ma, Heather A. Hirsch, Terrill K. McClanahan, Raymond J. Moniz, (unknown), Samik Basu, Yaolin Wang, Venkataraman Sriram, Joseph H. Phillips, Brian J. Long	1
10	Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma 2008 ·Journal of Asthma and Allergy ·Jing Ma, (unknown), Irene Kerr, Ruban Mangadu, Andrew A. Protter, Linda S. Higgins	16
11	Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. 2008 ·PubMed ·Satyanarayana Medicherla, Lingyun Li, Ying Jing, Ann M. Kapoun, (unknown), Yuwang Liu, Ruban Mangadu, Gilbert O’Young, Andrew A. Protter, George F. Schreiner, Darren H. Wong, Linda S. Higgins	54
12	A Selective p38α Mitogen-Activated Protein Kinase Inhibitor Reverses Cartilage and Bone Destruction in Mice with Collagen-Induced Arthritis 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Satyanarayana Medicherla, Ying Jing, Ruban Mangadu, Yebin Jiang, Jenny Zhao, Ramona G. Almirez, Irene Kerr, Elizabeth G. Stebbins, Gilbert O’Young, Ann M. Kapoun, Gregory R. Luedtke, Sarvajit Chakravarty, Sundeep Dugar, Harry K. Genant, Andrew A. Protter	65
13	Preventive and Therapeutic Potential of p38α-Selective Mitogen-Activated Protein Kinase Inhibitor in Nonobese Diabetic Mice with Type 1 Diabetes 2006 ·Journal of Pharmacology and Experimental Therapeutics ·Satyanarayana Medicherla, Andrew A. Protter, Ying Jing, Ruban Mangadu, Ramona G. Almirez, Bruce Koppelman, Irene Kerr, Tony Navas, (unknown), (unknown), Yuwang Liu, (unknown), John Perumattam, Babu Mavunkel, Sundeep Dugar, George F. Schreiner	13
14	Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia 2004 ·Pain ·Sarah M. Sweitzer, Michael C. Peters, (unknown), (unknown), Ruban Mangadu, Sarvajit Chakravarty, Sundeep Dugar, Satyanarayana Medicherla, Andrew A. Protter, David C. Yeomans	49
15	SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma CellsIn vitroandIn vivo 2004 ·Cancer Research ·Martin Uhl, Steffen Aulwurm, Jörg Wischhusen, Markus Weiler, Ying Jing, Ramona G. Almirez, Ruban Mangadu, (unknown), Michael Platten, Ulrich Herrlinger, Alison Murphy, Darren H. Wong, Wolfgang Wick, Linda S. Higgins, Michael Weller	349

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact